Patent Law
4 articles on Patent Law, researched and written by the Shotlee Editorial Team from primary sources.
Hims & Hers, Novo Nordisk End Lawsuit, Collaborate on Wegovy Sales
In a surprise turn, Novo Nordisk is dropping its lawsuit against Hims & Hers Health, paving the way for branded Wegovy and Ozempic sales on the telehealth platform. This follows Hims' brief plan for cheaper compounded versions and FDA warnings on shortages. Patients gain better access to approved GLP-1 medications.
5 min read
Hims & Hers GLP-1 Pill Launch Backfires, Fuels Compounder Crackdown
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
6 min read
Delhi HC Rejects Stay on Order Permitting Dr. Reddy's Semaglutide Export
The Delhi High Court has upheld a previous ruling that allows Dr. Reddy's Laboratories to manufacture Semaglutide for export. This decision comes amid an ongoing patent dispute with Novo Nordisk, who claims Dr. Reddy's infringed on their Semaglutide patent.
3 min read
Dr. Reddy's Cleared by Delhi HC to Export Semaglutide Generics of Novo Nordisk
An Indian court has granted Dr. Reddy's Laboratories Ltd permission to manufacture and export generic versions of Novo Nordisk's diabetes and obesity medications. This decision comes before the global patent expirations in 2026. The ruling allows export to countries without patent protection.
2 min read